{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:55:14Z","timestamp":1792706114714,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"DOI":"10.1186\/s13065-025-01503-4","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T20:11:09Z","timestamp":1747771869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Green and sustainable LC-APCI-MS\/MS method for simultaneous quantification of genotoxic nitrosamines in antidiabetic medication: sitagliptin"],"prefix":"10.1186","volume":"19","author":[{"given":"Sriram","family":"Pepakayala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Nadh","family":"Ratnakaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuvaraj","family":"Zunjarrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh Kumar","family":"Lohia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"issue":"9","key":"1503_CR1","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.3390\/ijms23094559","volume":"23","author":"Y Li","year":"2022","unstructured":"Li Y, Hecht SS. Metabolic activation and DNA interactions of carcinogenic N-nitrosamines to which humans are commonly exposed. Int J Mol Sci. 2022;23(9):4559. https:\/\/doi.org\/10.3390\/ijms23094559.","journal-title":"Int J Mol Sci"},{"key":"1503_CR2","doi-asserted-by":"publisher","DOI":"10.3791\/56312","author":"ES Carlson","year":"2017","unstructured":"Carlson ES, Upadhyaya P, Hecht SS. A general method for detecting nitrosamide formation in the in vitro metabolism of nitrosamines by cytochrome P450s. J Visual Exp. 2017. https:\/\/doi.org\/10.3791\/56312.","journal-title":"J Visual Exp"},{"key":"1503_CR3","unstructured":"Guideline IH. Assessment and control of dna reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH): Geneva. 2014"},{"issue":"2","key":"1503_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1208\/s12249-023-02523-w","volume":"24","author":"NA Charoo","year":"2023","unstructured":"Charoo NA, Dharani S, Khan MA, Rahman Z. Nitroso impurities in drug products: an overview of risk assessment, regulatory milieu, and control strategy. AAPS PharmSciTech. 2023;24(2):60. https:\/\/doi.org\/10.1208\/s12249-023-02523-w.","journal-title":"AAPS PharmSciTech"},{"key":"1503_CR5","unstructured":"European Medicines Agency. Assessment report on nitrosamine impurities. EMEA\/H\/A5(3)\/1490. 2020. Nitrosamines EMEA-H-A5(3)-1490\u2014Assessment Report."},{"issue":"6","key":"1503_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2174\/156802607780091028","volume":"7","author":"NA Thornberry","year":"2007","unstructured":"Thornberry NA, Weber AE. Discovery of JANUVIA\u2122(Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. Curr Top Med Chem. 2007;7(6):557\u201368. https:\/\/doi.org\/10.2174\/156802607780091028.","journal-title":"Curr Top Med Chem"},{"issue":"6","key":"1503_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1586\/17446651.3.6.691","volume":"3","author":"JK Bardsley","year":"2008","unstructured":"Bardsley JK, Ratner RE. Sitagliptin: an oral agent for glucose control. Expert rev endocrinol metab. 2008;3(6):691\u20137. https:\/\/doi.org\/10.1586\/17446651.3.6.691.","journal-title":"Expert rev endocrinol metab"},{"key":"1503_CR8","unstructured":"Manne SR, Sajja E, Satyanarayana R, Bairy KR, Aluru S. Process for the preparation of sitagliptin and its intermediates, World Intellectual Property Organization, 28 October 2010, Patent International Publication Number WO2010122578A2"},{"issue":"2","key":"1503_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jsps.2022.12.010","volume":"31","author":"W Wichitnithad","year":"2023","unstructured":"Wichitnithad W, Nantaphol S, Noppakhunsomboon K, Rojsitthisak P. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals. Saudi Pharma J. 2023;31(2):295\u2013311. https:\/\/doi.org\/10.1016\/j.jsps.2022.12.010.","journal-title":"Saudi Pharma J"},{"issue":"116","key":"1503_CR10","doi-asserted-by":"publisher","first-page":"104749","DOI":"10.1016\/j.yrtph.2020.104749","volume":"1","author":"A Thresher","year":"2020","unstructured":"Thresher A, Foster R, Ponting DJ, Stalford SA, Tennant RE, Thomas R. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Regul Toxicol Pharm. 2020;1(116):104749. https:\/\/doi.org\/10.1016\/j.yrtph.2020.104749.","journal-title":"Regul Toxicol Pharm"},{"issue":"5","key":"1503_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/em.22446","volume":"62","author":"GE Johnson","year":"2021","unstructured":"Johnson GE, Dobo K, Gollapudi B, Harvey J, Kenny J, Kenyon M, Lynch A, Minocherhomji S, Nicolette J, Thybaud V, Wheeldon R. Permitted daily exposure limits for noteworthy N-nitrosamines. Environ Mol Mutagen. 2021;62(5):293\u2013305. https:\/\/doi.org\/10.1002\/em.22446.","journal-title":"Environ Mol Mutagen"},{"issue":"150","key":"1503_CR12","doi-asserted-by":"publisher","first-page":"105640","DOI":"10.1016\/j.yrtph.2024.105640","volume":"1","author":"NL Kruhlak","year":"2024","unstructured":"Kruhlak NL, Schmidt M, Froetschl R, Graber S, Haas B, Horne I, Horne S, King ST, Koval IA, Kumaran G, Langenkamp A. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: development and application of the Carcinogenic Potency Categorization Approach (CPCA). Regul Toxicol Pharm. 2024;1(150):105640. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105640.","journal-title":"Regul Toxicol Pharm"},{"issue":"164","key":"1503_CR13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jpba.2018.11.023","volume":"5","author":"A Gumieniczek","year":"2019","unstructured":"Gumieniczek A, Berecka A, Mroczek T, Wojtanowski K, D\u0105browska K, St\u0119pie\u0144 K. Determination of chemical stability of sitagliptin by LC-UV, LC-MS and FT-IR methods. J Pharma Biomed Anal. 2019;5(164):789\u2013807. https:\/\/doi.org\/10.1016\/j.jpba.2018.11.023.","journal-title":"J Pharma Biomed Anal"},{"issue":"9","key":"1503_CR14","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.14233\/ajchem.2017.20632","volume":"29","author":"NR Vuyyuru","year":"2017","unstructured":"Vuyyuru NR, Krishna GV, Ramadevi B, Kumar YR. Evaluation of process impurities and degradants of sitagliptin phosphate by validated stability indicating RP-LC method. Asian J Chem. 2017;29(9):1941\u20137. https:\/\/doi.org\/10.14233\/ajchem.2017.20632.","journal-title":"Asian J Chem"},{"issue":"8","key":"1503_CR15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1691\/ph.2018.7201","volume":"73","author":"CF Giordani","year":"2018","unstructured":"Giordani CF, Campanharo S, Wingert NR, Bueno LM, Manoel JW, Garcia C, Volpato NM, Schapoval EE, Steppe M. Determination of sitagliptin in the presence of its organic impurities using Box-Behnken experimental design for robustness assessment. Pharmazie. 2018;73(8):442\u20136. https:\/\/doi.org\/10.1691\/ph.2018.7201.","journal-title":"Pharmazie"},{"issue":"202","key":"1503_CR16","doi-asserted-by":"publisher","first-page":"114163","DOI":"10.1016\/j.jpba.2021.114163","volume":"5","author":"B Pasquini","year":"2021","unstructured":"Pasquini B, Gotti R, Villar-Navarro M, Dou\u0161a M, Renai L, Del Bubba M, Orlandini S, Furlanetto S. Analytical quality by design in the development of a solvent-modified micellar electrokinetic chromatography method for the determination of sitagliptin and its related compounds. J Pharma Biomed Anal. 2021;5(202):114163. https:\/\/doi.org\/10.1016\/j.jpba.2021.114163.","journal-title":"J Pharma Biomed Anal"},{"issue":"3","key":"1503_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.11973\/lhjy-hx202303010","volume":"59","author":"MU Lina","year":"2023","unstructured":"Lina MU, Shubo DONG, Jiajia WEI, Anqi ZHOU, Yong CHEN, Hanyue YANG, Zhenming ZHANG, Yongjian YANG. Determination of ethylenediamine as the genotoxic impurity in sitagliptin phosphate by high performance liquid chromatography tandem mass spectrometry. Phy Test Chem Anal Part B. 2023;59(3):321\u20135. https:\/\/doi.org\/10.11973\/lhjy-hx202303010.","journal-title":"Phy Test Chem Anal Part B"},{"issue":"3","key":"1503_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1039\/D2AY01821G","volume":"15","author":"Z Wang","year":"2023","unstructured":"Wang Z, Hu S, Wu X, He Z, Ke C, Hu M. A highly sensitive LC-MS\/MS method for the determination and quantification of a recently identified N-nitrosamine impurity in the sitagliptin phosphate monohydrate active pharmaceutical ingredient. Anal Methods. 2023;15(3):256\u201360. https:\/\/doi.org\/10.1039\/D2AY01821G.","journal-title":"Anal Methods"},{"issue":"23","key":"1503_CR19","doi-asserted-by":"publisher","first-page":"8581","DOI":"10.3390\/molecules27238581","volume":"27","author":"HN Chittireddy","year":"2022","unstructured":"Chittireddy HN, Kumar JS, Bhimireddy A, Shaik MR, Khan M, Adil SF, Khan M, Aldhuwayhi FN. Development and validation for quantification of 7-nitroso impurity in sitagliptin by ultraperformance liquid chromatography with triple quadrupole mass spectrometry. Molecules. 2022;27(23):8581. https:\/\/doi.org\/10.3390\/molecules27238581.","journal-title":"Molecules"},{"issue":"238","key":"1503_CR20","doi-asserted-by":"publisher","first-page":"115861","DOI":"10.1016\/j.jpba.2023.115861","volume":"20","author":"J Jire\u0161","year":"2024","unstructured":"Jire\u0161 J, Dou\u0161a M, Gibala P, Doubsk\u00fd J, P\u011b\u010dek D, Mervart D, Kluk A, Veseli A, Kal\u00e1\u0161ek S, \u0158ezanka P. Comprehensive UHPLC\u2013MS screening methods for the analysis of triazolopyrazine precursor and its genotoxic nitroso-derivative in sitagliptin pharmaceutical formulation. J Pharma Biomed Anal. 2024;20(238):115861. https:\/\/doi.org\/10.1016\/j.jpba.2023.115861.","journal-title":"J Pharma Biomed Anal"},{"issue":"2","key":"1503_CR21","doi-asserted-by":"publisher","first-page":"100053","DOI":"10.1016\/j.jcoa.2022.100053","volume":"1","author":"NK Nagendla","year":"2022","unstructured":"Nagendla NK, Shaik H, Subrahanyam SB, Godugu D, Mudiam MK. Development, validation, and estimation of measurement uncertainty for the quantitative determination of nitrosamines in Sartan drugs using liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. J Chromatogr. 2022;1(2):100053. https:\/\/doi.org\/10.1016\/j.jcoa.2022.100053.","journal-title":"J Chromatogr"},{"key":"1503_CR22","unstructured":"Lame ME, Hatch L. High sensitivity quantitation of nitrosamine genotoxic impurities: LC-MS analysis of Ranitidine drug product using the Waters ACQUITY UPLC I-Class. Xevo TQ-XS Tandem Quadrupole Mass Spectrometer. Waters Corporation Application Note. 2020"},{"key":"1503_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-800871-3.00001-8","volume-title":"Mass spectrometry for the clinical laboratory","author":"W Clarke","year":"2017","unstructured":"Clarke W. Mass spectrometry in the clinical laboratory: determining the need and avoiding pitfalls. In: Mass spectrometry for the clinical laboratory. Cambridge: Academic Press; 2017. p. 1\u201315. https:\/\/doi.org\/10.1016\/B978-0-12-800871-3.00001-8."},{"key":"1503_CR24","volume-title":"Dictionary of mass spectrometry","author":"AI Mallet","year":"2010","unstructured":"Mallet AI, Down S. Dictionary of mass spectrometry. Hoboken: John Wiley & Sons; 2010."},{"key":"1503_CR25","unstructured":"Trends G. Challenges and opportunities in the implementation of the Sustainable Development Goals. United Nations Development Programme& United Nations Research Institute for Social Development. 2017: 0\u20133."},{"key":"1503_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/9783527831708.ch13","volume-title":"Method validation in pharmaceutical analysis: a guide to best practice","author":"J Ermer","year":"2025","unstructured":"Ermer J. ICH Q2 (R2): validation of analytical procedures. In: Method validation in pharmaceutical analysis: a guide to best practice. Hoboken: Wiley; 2025. p. 351\u201372. https:\/\/doi.org\/10.1002\/9783527831708.ch13."},{"issue":"1","key":"1503_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/jac.12220","volume":"204","author":"M Kozak","year":"2018","unstructured":"Kozak M, Piepho HP. What\u2019s normal anyway? Residual plots are more telling than significance tests when checking ANOVA assumptions. J Agron Crop Sci. 2018;204(1):86\u201398. https:\/\/doi.org\/10.1111\/jac.12220.","journal-title":"J Agron Crop Sci"},{"key":"1503_CR28","unstructured":"Biba E. General Chapter <1469> Nitrosamine Impurities. USP: The Standard of Trust; 2010. 2020."},{"issue":"3","key":"1503_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/analytica5030030","volume":"5","author":"FR Mansour","year":"2024","unstructured":"Mansour FR, P\u0142otka-Wasylka J, Locatelli M. Modified GAPI (MoGAPI) tool and software for the assessment of method greenness: case studies and applications. Analytica. 2024;5(3):451\u20137. https:\/\/doi.org\/10.3390\/analytica5030030.","journal-title":"Analytica"},{"issue":"14","key":"1503_CR30","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira F, Wojnowski W, Tobiszewski M. AGREE\u2014Analytical GREEnness metric approach and software. Anal Chem. 2020;92(14):10076\u201382. https:\/\/doi.org\/10.1021\/acs.analchem.0c01887.","journal-title":"Anal Chem"},{"issue":"37","key":"1503_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","volume":"1","author":"A Ga\u0142uszka","year":"2012","unstructured":"Ga\u0142uszka A, Migaszewski ZM, Konieczka P, Namie\u015bnik J. Analytical Eco-Scale for assessing the greenness of analytical procedures. TrAC Trends in Anal Chem. 2012;1(37):61\u201372. https:\/\/doi.org\/10.1016\/j.trac.2012.03.013.","journal-title":"TrAC Trends in Anal Chem"},{"key":"1503_CR32","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.sampre.2025.100164","volume":"14","author":"FR Mansour","year":"2025","unstructured":"Mansour FR, Bedair A, Locatelli M. Click analytical chemistry index as a novel concept and framework, supported with open-source software to assess analytical methods. Adv Sam Prep. 2025;14:100164. https:\/\/doi.org\/10.1016\/j.sampre.2025.100164.","journal-title":"Adv Sam Prep"}],"updated-by":[{"DOI":"10.1186\/s13065-025-01563-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000}}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01503-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-025-01503-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01503-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T05:52:45Z","timestamp":1751089965000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-025-01503-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1186\/s13065-025-01503-4","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The missing Abstract included in the article PDF","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13065-025-01563-6","URL":"https:\/\/doi.org\/10.1186\/s13065-025-01563-6","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}